Angelman syndrome is a neurodevelopmental disorder caused by a deficiency of the ubiquitin protein ligase UBE3A in the brain.
Applications related to any area of research involving Angelman syndrome will be considered; the highest priority will be given to pilot projects to test new ideas about the pathogenesis of, therapy for and educational best practices in Angelman syndrome. Researchers from all countries are encouraged to apply.
One-year grants will be awarded for amounts of up to $100,000. The application should include the following:
One-page summary abstract of proposed research
Proposal of up to five pages, including hypothesis, background, methods, significance of the proposed research and identification of the primary investigator
One-page detailed budget
Curriculum vitae of the applicant
No indirect costs will be allowed. Proposals involving human or animal subjects must be approved by institutional review boards before funding is released.
The application deadline is June 30, 2006. A cover letter and 15 copies of the proposals should be submitted to the Angelman Syndrome Foundation, 3015 East New York Street, Suite A2265, Aurora, IL 60504. Questions about this announcement should be directed to Joseph Wagstaff, M.D., Ph.D.; telephone: (704) 355-6091.
|< Prev||Next >|